Skip to main content
. 2014 Sep 2;9(11):1857–1867. doi: 10.2215/CJN.09430913

Figure 2.

Figure 2.

Association between the biomarker panel and AKI progression and death, as well as biomarker elevation and outcomes. (A) Association between the number of biomarkers above their optimal cutoff for AKI progression and death and the unadjusted and adjusted relative risk for this outcome. All values are relative to having no markers over their cutoffs (n=65). Markers used in the panel include NGAL, IL-18, L-FABP, and albumin. The adjusted model is adjusted for CKD stage, demographics (race, age, and sex), MELD score, and serum sodium. The 95% confidence intervals for adjusted relative risks are as follows: one marker, 1.21 to 10.67; two markers, 1.25 to 11.40; three markers, 1.62 to 13.72; and four markers, 2.32 to 20.46. Biomarker cutoffs are as follows: NGAL, 287 ng/ml; IL-18, 55 pg/ml; L-FABP, 21 ng/ml; and albumin, 41 mg/dl. (B) Association between biomarker elevation and outcomes. The percentage of patients without AKI progression or death, progression alone and progression and death by the number of biomarkers of structural injury above their optimal cutoff for prediction of progression and death. Biomarkers included in the panel include NGAL, IL-18, L-FABP, and albumin. MELD, model of end stage liver disease.